Investor Tips New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt. Articles You May Like 5 Spectacular Earnings Charts How Rising AI Power Demand Is Fueling Utility ETFs Brian’s Big Idea: Three Tech Stocks And A Popular Service at Zacks Worried About an AI Bubble? Look to Surging International Stocks